SOTAC — Sotac Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- IN₹1.53bn
- IN₹2.00bn
- IN₹969.87m
- 45
- 28
- 61
- 41
Annual income statement for Sotac Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 488 | 732 | 580 | 1,038 | 970 |
| Cost of Revenue | |||||
| Gross Profit | 94.5 | 172 | 179 | 242 | 287 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 500 | 681 | 514 | 986 | 872 |
| Operating Profit | -11.4 | 50.1 | 65.8 | 51.8 | 98 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20.6 | 46.9 | 59.6 | 39.6 | 111 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.7 | 28.8 | 45 | 35.8 | 92.8 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.7 | 28.8 | 45 | 35.8 | 80.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.7 | 28.8 | 45 | 35.8 | 80.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.14 | 3.62 | 4.07 | 3.24 | 7.26 |
| Dividends per Share |